TNFα and IFNγ enhance MUC16 expression in breast, endometrial, and ovarian cancer cells through the NFκB pathway, with this upregulation linked to immune regulatory factor activity, indicating that MUC16 modulation may benefit treatment (38). The gene discussed is IFNG; the disease is ovarian carcinoma.